Abstract
Prostaglandin F2 alpha (PGF2a) analogues including bimatoprost and travoprost are used worldwide, often as first line topical treatments for glaucoma. We present 2 cases of a newly described side effect of both these topical agents in terms of periorbital fat atrophy. This visually noticeable side effect had features demonstrable on MRI scanning. The periorbital fat atrophy is most apparent with uniocular use and both doctors and patients need to be aware of this side effect before commencing treatment. The effects, however, appear to be reversible with treatment cessation.
MeSH terms
-
Adipose Tissue / drug effects
-
Adipose Tissue / pathology*
-
Administration, Topical
-
Aged, 80 and over
-
Amides / administration & dosage
-
Amides / adverse effects
-
Atrophy / chemically induced
-
Atrophy / pathology
-
Bimatoprost
-
Cloprostenol / administration & dosage
-
Cloprostenol / adverse effects
-
Cloprostenol / analogs & derivatives
-
Female
-
Follow-Up Studies
-
Glaucoma / drug therapy
-
Humans
-
Magnetic Resonance Imaging / methods
-
Male
-
Middle Aged
-
Orbital Diseases / chemically induced*
-
Orbital Diseases / diagnosis
-
Prostaglandins, Synthetic / adverse effects*
-
Prostaglandins, Synthetic / therapeutic use
-
Travoprost
Substances
-
Amides
-
Prostaglandins, Synthetic
-
Cloprostenol
-
Bimatoprost
-
Travoprost